user-generated· price
AstraZeneca shares fall below peer average valuation by Q4 2026
AstraZeneca’s valuation premium over European pharma peers will erode further following the Wainua trial failure, with shares trading below the sector average by December 31, 2026. The company’s long-term growth narrative will face increased scrutiny as investors reassess pipeline reliability.
price · Prediction Market
- Implied probability (Yes)
- 70%
- Closes
- 2026-12-31
More price markets
- Samsung Electronics market cap to exceed $1.2T by Q3 2026 — 78% Yes
- Cisco stock to rise above $65 by Q3 2026 — 72% Yes
- Private jet charter prices increase 20% in 2027 — 75% Yes
- Google Messages sees 30% user growth in 6 months post-launch — 70% Yes
- US AI chip ETF doubles in value by 2026-09-30 — 65% Yes
- X’s stock price rises 10% within 3 months of History tab launch — 55% Yes
- TSK enters top 5 Spanish engineering firms by market cap — 60% Yes
- Ford stock volatility exceeds 60% annualized within 6 months — 75% Yes
Loading…